News Release：2026 | Eisai Co., Ltd.

• Corporate

Notification Regarding Receipt of Dividend from a Consolidated Subsidiary

• Sustainability

Eisai Donates 8,250 Drinking Cups to Support Lymphatic Filariasis Elimination Efforts in Papua New Guinea
Employee-led Sustainability One-Coin Donation Project supports frontline health services in collaboration with JICA and Toyota Tsusho (PNG) Ltd., Trading as Ela Motors

• R&D
• Products

U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
Approval based on results from the Phase 3 LITESPARK-011 trial evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced ccRCC following treatment with a PD-1/PD-L1 inhibitor
WELIREG plus LENVIMA is the first approved combination of a HIF-2 alpha inhibitor and a multi-targeted VEGFR-TKI for these patients

• R&D
• Products

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease

• Corporate

Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)

• R&D
• Products

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative Disease

• Products

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
An Important Step Forward for Access to LEQEMBI® for Eligible Patients in Canada

• Products

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.)

• Corporate

WashU Medicine Honors CEO Haruo Naito and Eisai for Longstanding Contributions to Alzheimer’s Disease Research and Healthcare

• Corporate

Eisai Supports Relief Efforts for the 2026 Kumamoto Earthquake

• Corporate
• Products

Revenue of LEQEMBI® (Preliminary Basis)

• Corporate
• Products

Pfizer and Eisai Commence Co-promotion of “NURTEC®” for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

• R&D
• Products

Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)

• R&D
• Products

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting

• R&D
• Products

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.)
U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026

• R&D

Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer’s Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer’s Association International Conference® (AAIC®) 2026
Measuring the plasma eMTBR-tau243 biomarker may serve as a practical, less invasive method of capturing Alzheimer's disease-specific pathological changes and may play an important role in etalanetug’s future clinical development

• R&D
• Products

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners

• R&D
• Products

Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)

• R&D
• Products

Eisai to Showcase Alzheimer’s Disease Portfolio with More Than 50 Presentations at the Alzheimer’s Association International Conference® 2026 (AAIC®)

• Corporate
• R&D

UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases

• R&D

Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
A Marketing Authorisation Application with the European Medicines Agency is also under regulatory review for approval

• Corporate

Eisai Announces Strategic Investment Supported by the UK Government’s LSIMF
Strategic investment in the Hatfield manufacturing site in the UK to help establish in-house capabilities for medicines requiring cold-chain management

• Corporate

Notification Regarding Issuance of Unsecured Straight Bonds

• R&D
• Products

Eisai Deepens Body of Clinical Evidence for LENVIMA® (Lenvatinib) Across Established Indications at ASCO 2026

• Corporate

Eisai Selected for “SX Brands” 2026 for the First Time

• Corporate

Notification Regarding the Disposal of Treasury Stock in Connection with the Continuation of the Stock Compensation System (Officers’ Compensation BIP Trust)

• Corporate

Notification Regarding the Continuation of the Stock Compensation System (Officers’ Compensation BIP Trust)

• R&D
• Products

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

• Corporate
• Products

Revenue of LEQEMBI® (Preliminary Basis)

• R&D
• Products

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

• R&D
• Products

Application Submitted for LENVIMA® (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG® (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

• R&D

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline
Additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories
Taletrectinib is already approved in the U.S., China and Japan for advanced ROS1-positive non-small cell lung cancer

• Corporate

Notice of Nominees for Directors

• R&D
• Products

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment

• Products

Regarding Discontinuation of Administration of “Tazverik® Tablets 200mg” (tazemetostat hydrobromide)

• Corporate

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation

• Corporate
• Ecosystem

Have Fun Exploring Sleep with Pokémon!
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokémon Sleep" Collaboration

• R&D
• Products

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting

• R&D
• Products

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
This is the first positive Phase 3 trial of a multi-targeted tyrosine kinase inhibitor in combination with a HIF-2 alpha inhibitor, the first for patients with RCC whose disease progressed on or after treatment with anti-PD-1/L1 therapy, and the first to improve PFS compared to a modern tyrosine kinase inhibitor

Based on these data, the U.S. FDA accepts for review two supplemental New Drug Applications for WELIREG plus LENVIMA in certain previously treated patients with advanced RCC

• R&D

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy

• Corporate

Eisai Announces Appointment of Corporate Officers

• R&D
• Products

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China

• Corporate
• Products

Revenue of LEQEMBI® (Preliminary Basis)

• Corporate
• R&D

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

• R&D
• Products

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease

FDA action date set for May 24, 2026

• Corporate
• Sustainability

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE TENTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY

• Corporate
• R&D

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Eisai will receive exclusive development, registration and commercialization rights for taletrectinib for the treatment of ROS1-positive non-small cell lung cancer in Europe, the Middle East, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India

Nuvation Bio will receive double-digit tiered royalties up to the high-teens as a percentage of taletrectinib sales in the licensed territories, in addition to up to €195 million (approx. USD $230 million) in upfront and milestone payments

Taletrectinib is already approved in the U.S., China, and Japan for advanced ROS1-positive non-small cell lung cancer

• Corporate

Changes of Corporate Officers

• R&D
• Products

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer
an at-home injection from the initiation of treatment for this progressive, relentless disease